JPS61100528A - ニフエジピン含有薬剤組成物とその製造方法 - Google Patents

ニフエジピン含有薬剤組成物とその製造方法

Info

Publication number
JPS61100528A
JPS61100528A JP60206703A JP20670385A JPS61100528A JP S61100528 A JPS61100528 A JP S61100528A JP 60206703 A JP60206703 A JP 60206703A JP 20670385 A JP20670385 A JP 20670385A JP S61100528 A JPS61100528 A JP S61100528A
Authority
JP
Japan
Prior art keywords
nifedipine
polyethylene glycols
pharmaceutical composition
mixture
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60206703A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0579651B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
ハンス　ケーネ
ウオルフガンク　ラール
ハイン　ウヴエ　シユメルザール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Rentschler Arzneimittel GmbH and Co KG
Original Assignee
Dr Rentschler Arzneimittel GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6248592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS61100528(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Rentschler Arzneimittel GmbH and Co KG filed Critical Dr Rentschler Arzneimittel GmbH and Co KG
Publication of JPS61100528A publication Critical patent/JPS61100528A/ja
Publication of JPH0579651B2 publication Critical patent/JPH0579651B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
JP60206703A 1984-10-23 1985-09-20 ニフエジピン含有薬剤組成物とその製造方法 Granted JPS61100528A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3438830.3 1984-10-23
DE19843438830 DE3438830A1 (de) 1984-10-23 1984-10-23 Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
JPS61100528A true JPS61100528A (ja) 1986-05-19
JPH0579651B2 JPH0579651B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-11-04

Family

ID=6248592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60206703A Granted JPS61100528A (ja) 1984-10-23 1985-09-20 ニフエジピン含有薬剤組成物とその製造方法

Country Status (5)

Country Link
US (1) US4894235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0182007B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS61100528A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE57470T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3438830A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03506040A (ja) * 1989-05-16 1991-12-26 メデイス　ヘミツシユ―フアルマツオイテイツシエ　フアブリーク　ピユター　ゲーエムベーハー　ウント　コンパニー　カーゲー 調合薬剤
JP2010159296A (ja) * 2005-02-21 2010-07-22 Suheung Capsule Co Ltd フィルム強度を高めたゼラチン硬カプセル

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
DE3635522A1 (de) * 1986-10-18 1988-04-28 Euro Celtique Sa Pharmazeutische zusammensetzung
ATE68704T1 (de) * 1986-12-18 1991-11-15 Bauer Kurt Heinz Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
CA2056032A1 (en) * 1990-11-29 1992-05-30 Minoru Aoki Hard capsule preparation
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6537504B1 (en) 1998-04-06 2003-03-25 Li Young Method and apparatus for concurrent and sequential multi-step reactions for producing a plurality of different chemical compounds
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
IL149186A0 (en) 1999-12-23 2002-11-10 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
OA12624A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers.
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ES2309294T3 (es) 2002-02-01 2008-12-16 Pfizer Products Inc. Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ES2333318T3 (es) 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
WO2005056542A1 (en) * 2003-12-09 2005-06-23 Pfizer Inc. Compositions comprising an hiv protease inhibitor
EP1753766A1 (en) 2004-05-25 2007-02-21 Pfizer Products Inc. Tetraazabenzo(e)azulene derivatives and analogs thereof
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20090163561A1 (en) * 2007-12-21 2009-06-25 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US8410127B2 (en) * 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CA2942759C (en) 2014-03-17 2018-01-09 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CN105092659B (zh) * 2015-08-28 2017-11-03 云南大学 基于Pt掺杂SnO2有序介孔薄膜的气体传感器制备方法
KR102779818B1 (ko) 2015-09-04 2025-03-11 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
KR20190035752A (ko) 2016-08-03 2019-04-03 사이머베이 쎄라퓨틱스, 인코퍼레이티드 염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
BR112019018688A2 (pt) 2017-03-10 2020-04-07 Pfizer derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
CR20210110A (es) 2018-08-31 2021-05-13 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
BR112021020295A2 (pt) 2019-04-19 2021-12-14 Pfizer Agentes antiproliferativos para o tratamento de pah
CN113874019A (zh) 2019-05-20 2021-12-31 辉瑞大药厂 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
WO2020261144A1 (en) 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
AU2021289169B2 (en) 2020-06-09 2024-01-04 Pfizer Inc. Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
CN120641401A (zh) 2022-10-07 2025-09-12 辉瑞公司 Hsd17b13抑制剂和/或降解剂
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
KR20250086775A (ko) 2022-10-18 2025-06-13 화이자 인코포레이티드 파타틴-유사 인산지질분해효소 도메인-함유 단백질 3(pnpla3) 개질제
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
KR20250117453A (ko) 2022-12-16 2025-08-04 화이자 인코포레이티드 3-플루오로-4-하이드록시벤즈아미드-함유 억제제 및/또는 분해제 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522631A (en) * 1978-08-07 1980-02-18 Ota Seiyaku Kk Readily absorbable nifedipine preparation
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3297804A (en) * 1964-05-19 1967-01-10 Ono Pharmaceutical Co Method of filling hard capsules with granules by the open-mouth-down punching method
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
SU432703A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE2209526C3 (de) * 1972-02-29 1980-02-28 Bayer Ag, 5090 Leverkusen Coronartherapeutlkum in Form von Gelatine-BeiBkapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
DE2614864C3 (de) * 1976-04-06 1979-11-29 Schwabe, Willmar, Dr., 7500 Karlsruhe Verfahren zur Herstellung Digoxin enthaltender Arzneipräparate in Weichgelatinekapseln zur oralen Verabfolgung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4454152A (en) * 1980-05-07 1984-06-12 Hoffmann-La Roche Inc. Methoxsalen dosage forms
DE3022137A1 (de) * 1980-06-13 1982-01-07 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum abfuellen von bei raumtemperatur hochviskosen pharmazeutischen massen in hartkapseln
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522631A (en) * 1978-08-07 1980-02-18 Ota Seiyaku Kk Readily absorbable nifedipine preparation
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03506040A (ja) * 1989-05-16 1991-12-26 メデイス　ヘミツシユ―フアルマツオイテイツシエ　フアブリーク　ピユター　ゲーエムベーハー　ウント　コンパニー　カーゲー 調合薬剤
JP2010159296A (ja) * 2005-02-21 2010-07-22 Suheung Capsule Co Ltd フィルム強度を高めたゼラチン硬カプセル

Also Published As

Publication number Publication date
EP0182007A2 (de) 1986-05-28
US4894235A (en) 1990-01-16
EP0182007B1 (de) 1990-10-17
DE3580154D1 (de) 1990-11-22
ATE57470T1 (de) 1990-11-15
EP0182007A3 (en) 1987-04-22
JPH0579651B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-11-04
DE3438830C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-04-11
DE3438830A1 (de) 1986-04-30

Similar Documents

Publication Publication Date Title
JPS61100528A (ja) ニフエジピン含有薬剤組成物とその製造方法
CA2159580C (en) Pharmaceutical compositions containing polyvinylpyrrolidone and a tri-ester and process of manufacture thereof
US5505961A (en) Gelatin capsules containing a highly concentrated acetaminophen solution
US5294615A (en) Terazosin polymorph and pharmaceutical composition
CN115427022B (zh) 药物组合物、制备方法及其使用方法
JPS61158921A (ja) イブプロフエン含有ゼラチン軟カプセルおよびその製造方法
JPH02286615A (ja) 経口投与用イブプロフェン組成物
JPS62114911A (ja) 経口投与型徐放性医薬製剤
FI85105B (fi) Suppositoriumbas.
JPS6389160A (ja) 安定な医薬用ゲル製剤
DK167139B1 (da) Fremgangsmaade til fremstilling af en stabil doseringsform af en pge2-forbindelse (prostaglandin e2)
EP0152292A2 (en) Acetaminophen gelatin capsules
EP0173293B1 (en) Hot melt antihistamine formulations
BRPI0713054A2 (pt) cápsulas sólidas enchidas com lìquido contendo ibuprofeno
JPH02115126A (ja) エトポシド溶液
JPS6036424A (ja) 液体潤滑剤を含有する医薬組成物
RU2165755C2 (ru) Композиция для лечения отита среднего уха с перфорацией и способ получения композиции
CN1172646A (zh) 含有抗气胀药的软明胶药物剂型的填充物质
CA1333774C (en) Soft capsular preparation of sodium picosulfate
JP2932086B2 (ja) 新規なピコスルファートナトリウム液充填硬カプセル剤
CN105055378B (zh) 一种盐酸美克洛嗪的口腔速释膜剂及其制备方法
KR100201907B1 (ko) 비페닐디메틸디카르복실레이트를 가용화시킨 연질캅셀제
RU2322968C1 (ru) Суппозитории
JPS62255424A (ja) ヒメクロモンの調剤及びその製造方法
JPH01226817A (ja) ４‐アロイルイミダゾール‐２‐オン類に対する製薬組成物